Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma

Rini, 2011, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, Lancet, 378, 1931, 10.1016/S0140-6736(11)61613-9 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Sternberg, 2010, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, J Clin Oncol, 28, 1061, 10.1200/JCO.2009.23.9764 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Rini, 2015, Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma, Ann Oncol, 26, 1372, 10.1093/annonc/mdv103 Rini, 2013, Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial, Lancet Oncol, 14, 1233, 10.1016/S1470-2045(13)70464-9 Klumpen, 2011, Moving towards dose individualization of tyrosine kinase inhibitors, Cancer Treat Rev, 37, 251, 10.1016/j.ctrv.2010.08.006 Kalra, 2015, Alternate sunitinib schedules in patients with metastatic renal cell carcinoma, Ann Oncol, 26, 1300, 10.1093/annonc/mdv030 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Heng, 2009, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J Clin Oncol, 27, 5794, 10.1200/JCO.2008.21.4809 Schag, 1984, Karnofsky performance status revisited: reliability, validity, and guidelines, J Clin Oncol, 2, 187, 10.1200/JCO.1984.2.3.187 Prasad, 2014, Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients, J Clin Oncol, 32, 1620, 10.1200/JCO.2013.53.0204 ClinicalTrials.gov. NCT01499121—Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule. Available at: https://clinicaltrials.gov/ct2/show/record/NCT01499121. Accessed: July 29, 2016. ClinicalTrials.gov. NCT02579811—Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02579811?term=axitinib&recr=Open&rank=9. Accessed July 29, 2016. Motzer, 2008, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, 372, 449, 10.1016/S0140-6736(08)61039-9 Motzer, 2015, Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol, 16, 1473, 10.1016/S1470-2045(15)00290-9 Motzer, 2016, Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma, Lancet Oncol, 17, e4, 10.1016/S1470-2045(15)00543-4 Choueiri, 2015, Cabozantinib versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1814, 10.1056/NEJMoa1510016 Jackisch, 2014, Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival—results from a prospective, observational study in Germany, Breast, 23, 603, 10.1016/j.breast.2014.06.003 Extra, 2010, Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study, Oncologist, 15, 799, 10.1634/theoncologist.2009-0029 Ou, 2014, Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC, Ann Oncol, 25, 415, 10.1093/annonc/mdt572 Li, 2012, Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients, World J Gastroenterol, 18, 698, 10.3748/wjg.v18.i7.698 Park, 2009, Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor, Jpn J Clin Oncol, 39, 105, 10.1093/jjco/hyn134 Adelaiye, 2015, Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications, Mol Cancer Ther, 14, 513, 10.1158/1535-7163.MCT-14-0208 Rini, 2013, Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis, J Clin Pharmacol, 53, 491, 10.1002/jcph.73 Suttle, 2014, Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma, Br J Cancer, 111, 1909, 10.1038/bjc.2014.503 Eechoute, 2012, A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients, Clin Cancer Res, 18, 5780, 10.1158/1078-0432.CCR-12-0490 Yu H, van Erp NP, Bins S, et al. Development of a pharmacokinetic model for pazopanib—a tyrosine kinase inhibitor used for the treatment of solid tumours. Population Approach Group in Europe 2016 Annual Meeting. 2016; abstract 5926.